Angelini Pharma to acquire Catalyst Pharmaceuticals in $4.1 billion deal
Updated
Updated · The Wall Street Journal · May 7
Angelini Pharma to acquire Catalyst Pharmaceuticals in $4.1 billion deal
10 articles · Updated · The Wall Street Journal · May 7
Angelini will pay $31.50 a share, a 21% premium to Catalyst's April 22 unaffected close, valuing the Nasdaq-listed rare-disease specialist at about 3.5 billion euros.
Both boards unanimously approved the transaction, which is expected to close in the third quarter of 2026 and will combine Catalyst's portfolio and commercial infrastructure with Angelini's brain-health business.
The acquisition gives Angelini Pharma entry into the US market, with Blackstone funds participating and BNP Paribas supporting financing, as the group seeks a scalable rare-disease platform and wider global therapy access.
Can Angelini navigate the hidden IP and cybersecurity risks to make its $4.1B U.S. market entry a success?
Will this transatlantic merger create a rare disease powerhouse, or will innovation get lost in the complexities of integration?